01-01-1970 12:00 AM | Source: Geojit Financial Services Ltd
Long Term : Buy Tata Consultancy Services Ltd For Target Rs.3,773 - Geojit Financial
News By Tags | #872 #4943 #409 #1302 #171

Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel

https://t.me/InvestmentGuruIndiacom

Download Telegram App before Joining the Channel

Strong exit from FY2021

Tata Consultancy Services, a division of Tata Sons Limited, is a global IT services organization that provides a comprehensive range of IT services to its clients in diverse industries. The Company, caters to finance and banking, insurance, telecommunication, transportation, retail, manufacturing, pharmaceutical, and utility industries.

* In Q4FY21, revenue rose 9.4% YoY (+4.2% QoQ and +5.9% YoY on constant currency CC basis), led by BFSI (+7.0% QoQ, +13.3% YoY in CC), Retail CPG (+4.0% QoQ, -0.9% YoY in CC) and Life sciences & Healthcare.

* EBIT margin expanded further to 26.8% (+20bps QoQ/+175bps YoY) supported by operating efficiency and large transformational deals. Resultantly, net profit surged 14.9% YoY to Rs. 9,246cr further benefitted by lower tax recorded during the quarter.

* We remain positive on the stock as large deal wins and strong order book continues to support company’s outlook. Additionally, operational efficiency and strong cash conversion cycle remains the key catalysts. We reiterate our BUY rating on the stock with a revised target price of Rs. 3,773 based on 31x FY23E adj. EPS.

 

Revenue remains robust with strong growth across the verticals

Topline grew 9.4% YoY to Rs. 43,705cr (+4.2% QoQ, +5.9% YoY on CC basis). BFSI revenue increased to Rs. 17,559cr (+7.0% QoQ, +13.3% YoY in CC), supported by large transformational deals and core transformation. Retail and Consumer Packed Food (CPG) was at Rs. 6,778cr (+4.0% QoQ, -0.9% YoY in CC) owing to poor performance in sub sectors. Life Sciences and Healthcare segment continued to remain strong (+3.8% QoQ, +19.3% YoY in CC). Also, Manufacturing business went up 3.9% QoQ/+1.3% YoY on CC. Besides this, Communications and Media, and Technology Services rose 1.8% QoQ, while declined -4.0% YoY on CC terms. EBIT grew 17.0% to Rs. 11,734cr, as EBIT margin expanded 175bps YoY to 26.8% aided by operating efficiency and large deal wins. Resultantly, net profit surged 14.9% YoY to Rs. 9,246cr.

 

Key concall highlights

* In Q4FY21, Company’s order book stood at USD 9.2bn, the highest ever number recorded by the company so far. Additionally, TCS also added higher ever employees count 19,388 in Q4FY21, taking total to 488,649 in FY21. While attrition rate (LTM) in IT services was at lowest 7.2% vs. 7.6% in Q3FY21.

* Management proposed final dividend of Rs.15 in Q4FY21.

 

Strong growth momentum aided by new products addition

TCS product portfolio continued to perform well in Q4FY21, Ignio signed up 15 new customers out of which 7 went live. Company upsell 21 products to its existing clients in Q4FY21. Overall, company added more than 50 customers for Ignio taking total to >200 in FY21. Additionally, TCS added 7 more reselling partners under channel partner program, won 2 more award under products suit and received 3 patent, with this company has 30 patents so far. Besides, TCS added 5 new wins and 5 go lives under financial domain TCS BaNCS, out of which biggest win was State Street in Q4FY21. Overall company recorded 19 wins for TCS BaNCS in FY21.

 

Valuation Outlook

remain promising on the back of strong order book, robust growth across the geography and diverse product portfolio. Additionally, strong growth momentum in core business verticals are likely to continue with strong order booking in BFSI, Retail, and CPG. We reiterate our BUY rating on the stock with a revised target price of Rs. 3,773 based on 31x FY23E adj. EPS.

 

To Read Complete Report & Disclaimer Click Here

 

For More Geojit Financial Services Ltd Disclaimer https://www.geojit.com/disclaimer 

SEBI Registration Number: INH200000345

 

Above views are of the author and not of the website kindly read disclaimer